HERVolution Publishes Foundational Data Demonstrating Rationally Engineered HERV-K Antigens Can Break Immune Tolerance and Train Immune Cells to Target Cancer Cells

Barchart · 5d ago

Peer-reviewed study describes the rationally engineered envelope modification underpinning HERVolution's lead program, IPT-001, and detects HERV-K expression across the majority of 43 cancer types in 1,353 patients

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.